CTKB · Cytek Biosciences, Inc.
Price & Indicators
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA loss non-GAAP | -$9.1M | first quarter of 2026 | — |
| Total installed base of Cytek instruments | 3,789 | first quarter of 2026 | — |
| Adjusted EBITDA non-GAAP | $4.5M | Q4 2025 | — |
| Adjusted EBITDA excluding investment income non-GAAP | -$3.1M | Full Year 2025 | — |
| Total instruments placed | 630 | Full Year 2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CTKB
this stock
Cytek Biosciences, Inc.
|
$575.98M | -9.7% | +6414.2% | — | 3.9% |
|
ABT
Abbott Laboratories
|
$179.51B | -19.2% | +5.7% | 28.9 | 1.4% |
|
SYK
Stryker Corp
|
$126.60B | -9.0% | +11.2% | 38.2 | 1.8% |
|
MDT
Medtronic plc
|
$106.51B | -13.9% | +8.4% | 22.3 | 1.5% |
|
BSX
Boston Scientific Corp
|
$65.77B | -54.3% | +5.5% | 18.5 | 1.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CTKB | -1.7% | +6.5% | -9.0% | +2.9% | -9.7% |
| SPY | -1.7% | +0.7% | +6.4% | -1.2% | +8.3% |
| vs SPY | -0.1% | +5.9% | -15.3% | +4.1% | -18.0% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.